Literature DB >> 17252255

[Bisphosphonates in oncology].

A A Kurth1, A Heidenreich, I Diel.   

Abstract

Since bone metastases occur as a result of hematogenous spreading of tumor cells, therapy with curative intent is no longer feasible and palliative options for treating and preventing skeletal events are essential. Today, bisphosphonates are established in the systemic treatment of bone metastases. This report provides an overview of molecular mechanisms of action and clinical data of bisphosphonates in patients with skeletal metastases of breast and prostate cancer as the most common solid tumors which spread to the bone.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17252255     DOI： 10.1007/s00132-007-1051-1

Source DB:  PubMed          Journal:  Orthopade        ISSN： 0085-4530            Impact factor:   1.087


  22 in total

Review 1.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

Review 2.  The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma.

Authors:  B I Carlin; G L Andriole
Journal:  Cancer       Date:  2000-06-15       Impact factor: 6.860

3.  Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer.

Authors:  M G Oefelein; V Ricchuiti; W Conrad; A Seftel; D Bodner; H Goldman; M Resnick
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

4.  Bisphosphonate treatment inhibits the growth of prostate cancer cells.

Authors:  M V Lee; E M Fong; F R Singer; R S Guenette
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

Review 5.  Bisphosphonates for breast cancer.

Authors:  N Pavlakis; Rl Schmidt; M Stockler
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

6.  Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.

Authors:  Trevor Powles; Sandy Paterson; John A Kanis; Eugene McCloskey; Sue Ashley; Alwynne Tidy; Kirsi Rosenqvist; Ian Smith; Lars Ottestad; Sandra Legault; Marjo Pajunen; Auli Nevantaus; Esa Männistö; Anne Suovuori; Sari Atula; Jaakko Nevalainen; Liisa Pylkkänen
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

7.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506

8.  Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.

Authors:  A H Paterson; T J Powles; J A Kanis; E McCloskey; J Hanson; S Ashley
Journal:  J Clin Oncol       Date:  1993-01       Impact factor: 44.544

9.  Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.

Authors:  J-J Body; I J Diel; M R Lichinitser; E D Kreuser; W Dornoff; V A Gorbunova; M Budde; B Bergström
Journal:  Ann Oncol       Date:  2003-09       Impact factor: 32.976

10.  A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

Authors:  David P Dearnaley; Matthew R Sydes; Malcolm D Mason; Mark Stott; Christopher S Powell; Anne C R Robinson; Peter M Thompson; Leslie E Moffat; Sharon L Naylor; Mahesh K B Parmar
Journal:  J Natl Cancer Inst       Date:  2003-09-03       Impact factor: 13.506
View more
  1 in total

Review 1.  Angiogenesis in the Development of Medication-Related Osteonecrosis of the Jaws: An Overview.

Authors:  Andreas Max Pabst; Maximilian Krüger; Sebastian Blatt; Thomas Ziebart; Roman Rahimi-Nedjat; Elisabeth Goetze; Christian Walter
Journal:  Dent J (Basel)       Date:  2016-12-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.